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-12.99 in followup-year2, p < 0.01). CONCLUSION: This two
year, prospective, observational study showed that compared to
oral antipsychotics, RLAI treatment was associated with greater
reduction in hospital stays and days in hospital in patients with
schizophrenia.
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OBJECTIVES: Schizophrenia care produces a substantial eco-
nomic burden. Interventions that reduce the need for resource
use are of interest to clinicians and payers. This study assessed
changes in mental health resource use following initiation of
paliperidone extended-release tablets (paliperidone ER) in the
three double-blind (DB) trials and their open-label extensions
(OLE). METHODS: A retrospective chart review generated
data on resource use during the 12 months before and after the
DB trials. Additional IRB approval and informed consent were
obtained for these reviews. Average number of inpatient and
ambulatory care services in the pre- and post-periods was cal-
culated, including use of bootstrap resampling methods to
assess statistical signiﬁcance of differences. Total person years
were calculated for the pre- and post-periods to account for
different lengths of observation. Separate analyses were also
performed by country. RESULTS: In this analysis, patients
(n = 79) were from the United States (38.0%), Canada (19.0%)
and Malaysia (43.0%). Mean (SD) patient age was 38.0
(10.4) years; and the majority of patients were male (73.4%).
Most (70.9%) patients received prior treatment with antipsy-
chotics. During the OLE, the mean paliperidone ER treatment
duration (SD) was 226.4 (142.3) days, and the mean dose
was 11.5 (2.2) mg. Overall, paliperidone ER patients used
fewer resources after drug initiation (mean reduction per
person year: days hospitalized = 12.1, p = 0.002; number of
emergency room visits = 0.3, p = 0.038; number of psychiatric-
related ofﬁce visits = 2.3, p < 0.001; number of psychotherapy
sessions = 0.4, p = 0.004). Subgroup analyses revealed that the
greatest reduction in most resource categories was found in the
US sites (e.g. mean reduction in days hospitalized per person
year = 19.7 in the US, 6.3 in Canada, and 7.1 in Malaysia).
CONCLUSIONS: In this post-hoc analysis, paliperidone ER
was associated with a statistically signiﬁcant reduction in
mental health resource use. Prospective studies are needed to
conﬁrm the ﬁndings.
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OBJECTIVE: To compare health care resource utilization and
costs of Major Depressive Disorder (MDD) adult patients
treated with escitalopram 10 mg who increase to 20 mg vs.
those who were switched to a SNRI. METHODS: Adult MDD
patients initiated on escitalopram 10 mg who either increased
to 20 mg escitalopram or switched to a SNRI were identiﬁed in
the IHCIS National Managed Care Database (2003–2006).
Patients who changed therapy within 60 days from escitalo-
pram initiation date (index date) were excluded. Outcomes
included rates of hospitalization and emergency visits, number
of emergency visits days, and health care costs, and were
reported for all cause and MDD-related. All outcomes were
estimated over a 3 months period post-therapy change (dose
increase or switching) and were descriptively compared
between the two groups. Multivariate regression analyses were
performed to further adjust for patient demographics, comor-
bidities and baseline health care resource use. RESULTS: Study
samples included 9379 patients who increased escitalopram
from 10 mg to 20 mg and 1215 patients who were switched
from 10 mg escitalopram to a SNRI. Compared to patients
who increased escitalopram dose, SNRI switchers experienced
higher rates of MDD-related hospitalizations (RR = 1.2,
p = 0.566), higher rates of MDD-related emergency visit
(RR = 1.6, p < 0.05), and higher number of emergency visit
days (RR = 1.5, p < 0.01) in the 3-month post-therapy change
period. Patients who switched to SNRI also had on average
$413 higher total costs (p < 0.001), which include $390 higher
drug costs (p < 0.001). Results from multivariate regression
analyses were consistent with ﬁndings from descriptive analy-
ses. SNRI switchers incurred $430 higher risk-adjusted total
costs (p < 0.0001). CONCLUSION: Compared to adult MDD
patients who increased escitalopram from 10 mg to 20 mg,
patients who switched to a SNRI had more MDD-related emer-
gency visits, as well as higher drug and total health care costs
during the 3-month post-therapy change period.
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OBJECTIVE: Acute psychiatric hospitalizations represent a
major cost driver of care for psychiatric disorders. This analysis
characterized the costs of psychiatric hospitalization in the United
States bymajor psychiatric disorders and payer type.METHODS:
The analysis utilized Premier’s Perspective database of de-
identiﬁed inpatient administrative claims. Data from 263,252
psychiatric hospitalizations were classiﬁed into: Schizophrenia,
Bipolar Disorder, Depression, Substance Use, and Other Psychi-
atric Disorder based on All Patient Reﬁned—Diagnosis Related
Group codes. Results were inﬂated to national estimates by
weighting each hospitalization based on representative demo-
graphics of all hospitals in the nation. Because reimbursed values
were not available, the primary metric for analyses was the cost of
providing service rather than charges.RESULTS:The total cost of
all psychiatric hospitalizations in 2006 dollars was $10.6 billion
with charges of $26.5 billion. Public payers covered most psychi-
atric hospitalizations, particularly for schizophrenia with a much
smaller difference for bipolar disorder, depression, and substance
use disorders. Length of stay was longest for schizophrenia (11.0
days) followed by bipolar disorder (7.8 days), depression (6.2
days), and substance use disorders (5.0 days). Regardless of
disorder, length of stay was longer for public payers (8.7 days)
than private payers (5.6 days) or self-pay (4.6 days). The average
per daywas inversely related to length of stay with the highest cost
for substance use disorders ($1034) followed by depression
($888), bipolar disorder ($852), and schizophrenia ($806).CON-
CLUSION: The cost of delivering care for psychiatric hospitaliza-
tions in the US was approximately $10.6 billion in 2006. This
estimate does not include some physicians fees and does not
capture the amount reimbursed to the hospitals. Althoughmost of
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the cost is covered by public payers, a sizable proportion (33–
37%) of the hospitalizations for bipolar disorder, depression, and
substance use disorders are covered by private payers.
MENTAL HEALTH—Patient-Reported Outcomes
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OBJECTIVE: This study evaluated antipsychotic use in Medic-
aid beneﬁciaries with a schizophrenic disorder and identiﬁed
factors associated with poor adherence. METHODS: This study
involved a retrospective cohort analysis of non-dual Florida
Medicaid recipients who had a medical claim indicating a
schizophrenic disorder (ICD-9-CM 295.XX) and received an
antipsychotic (APS) medication between July 1, 2004 and June
30, 2005. Patients were followed for one year after the ﬁrst APS
prescription. Adherence was measured using the Medication
Possession Ratio (MPR: deﬁned as unduplicated ambulatory
treatment days divided by the number of ambulatory days in the
period), medication persistence (days between the ﬁrst and last
antipsychotic in the follow-up period), and number of untreated
days. Logistic regression models were used to identify predictors
of poor adherence (MPR < 0.80). RESULTS: A total of 8828
patients met inclusion criteria. Mean (SD) age was 42.3
(13.7) years, 49% were female, and 36.8% were white.
Approximately 18% and 39% had pre-existing diagnoses of
substance abuse or other psychiatric conditions, respectively.
Mean (SD) MPR was 0.72 (0.3). The mean number of
untreated days was 47.4 (60.8), and mean persistence was
311.9 (102.5) days. Approximately 57% of patients had MPR
values between 0.8 and 1. Logistic regression indicated that
younger patients (<18 years), females, nonwhites, those with a
substance abuse diagnosis or who received antidepressants, and
those newly starting APS therapy were signiﬁcantly more likely
to be poorly adherent, while those treated with atypical or
injectable antipsychotics (vs. conventional orals) were less likely
to be poorly adherent. CONCLUSION: Several patient charac-
teristics are predictive of poor adherence to APS therapy. Study
ﬁndings may be informative to health plan administrators inter-
ested in identifying patients at risk for medication non-
adherence.
PMH47
THE RELATIONSHIP BETWEENTHE ANTIPSYCHOTIC
MEDICATION ADHERENCE AND PATIENT OUTCOMES
AMONG BIPOLAR DISORDER PATIENTS
Lage MJ1, Hassan M2
1HealthMetrics Outcomes Research, LLC, Groton, CT, USA,
2AstraZeneca Pharmaceuticals LP,Wilmington, DE, USA
OBJECTIVE: To examine the impact of antipsychotic medica-
tion adherence on outcomes among individuals diagnosed with
bipolar disorder. METHODS: An administrative claims data-
base for a commercially-insured population was used to identify
patients with bipolar disorder who were newly initiating treat-
ment with antipsychotics (January 2000–December 2006).
Patients were included if they were aged between 18–64 years,
had no diagnoses of dementia or schizophrenia, and were con-
tinuously insured from 6 months prior through 12 months post-
index date (N = 7769). Logistic stepwise regressions examined
the association between achievement of adherence goals and
patient outcomes (hospitalization or emergency room (ER) visit
for any reason, mental-health related hospitalizations or ER
visit), while controlling for demographic characteristics, type of
bipolar disorder, general health, and comorbidities. Adherence
was measured by the medication possession ratio (MPR).
RESULTS: The mean MPR was 41.65%, with 61.68% of indi-
viduals having an MPR of less than 0.50 and 78.67% having an
MPR of less than 0.75. A signiﬁcant reduction in the risk of
hospitalization (odds ratio [OR = 0.854]; 95% CI: 0.746–0.978)
or an ER visit for any cause (OR = 0.843; 95% CI: 0.744–0.955)
was associated with an MPR of 0.75 or more. An MPR of 0.80
or more was associated with a signiﬁcant reduction in the risk of
a mental-health related hospitalization (OR = 0.817; 95% CI:
0.699–0.954) while an MPR of 0.90 or more was associated with
a signiﬁcant reduction in the risk of a mental-health related
ER visit (OR = 0.705; 95% CI: 0.544–0.912). Incremental im-
provements in MPR from 0.75 to 0.95 were associated with
corresponding reductions (20 to 30%) in the risk of any hospi-
talization or ER visit. CONCLUSION: As medication adherence
improved, risk of hospitalization or ER visit declined, illustrating
the link between adherence and better outcomes among patients
with bipolar disorder.
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OBJECTIVE: Guidelines recommend use of antidepressants for a
minimum of six months in major depressive disorder in order to
decrease the risk of relapse. Persistence on treatment depends
both on efﬁcacy and tolerability. In clinical trials, escitalopram
has shown a better efﬁcacy and equivalent tolerability compared
with citalopram. This work compares persistence on treatment
at six months and associated economic consequences, for treat-
ment with escitalopram vs. citalopram. METHODS: Using US
denominator-based claims database PharMetrics (includes data
from 86 managed care health plans covering 45 million patients),
we included adult patients diagnosed with depression who
started escitalopram or citalopram between January 1, 2003 and
December 31, 2004. Six-months persistence was deﬁned as the
percentage of patients still on treatment at 6 months. We com-
pared persistence over time using Cox model, and health care
costs at 6 months using log-linear regression. Propensity scoring
was used to account for channelling by indication. RESULTS:
A total of 13,227 patients started escitalopram; 3,624 pa-
tients started citalopram. Persistence at 6 months was 20.4%
with escitalopram vs. 16.2% with citalopram (p < 0.001).
Escitalopram-treated patients were more likely to be persistent
over 6-months than citalopram-treated patients adjusted for their
baseline characteristics (HR = 0.896; 95%CI = [0.859–0.934]).
More were observed on citalopram than on escitalopram (7.8 vs.
6.2; p < 0.001). Total health care costs over 6-months (including
treatment cost) were non-signiﬁcantly lower for escitalopram-
treated patients than for citalopram-treated patients (-USD232
per patient; p = 0.2). Persisters at 6 months incurred less total
health care costs than non-persisters (-USD280 over the 6
months). CONCLUSION: Persistence at 6 months is higher on
escitalopram than on citalopram, in consistency with its better
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